Page 1

Studies open voor inclusie – Afdeling Medische Oncologie Fase I onderzoek en farmacokinetiek studies Externe code

Titel

Onderzoeker

MOGE13 M14AFS

Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype colorectal, non-small cell lung and pancreatic cancer

Herpen, van C.M.L.

MOMULT06 DIET

Improving the tolerability of the oral targeted anticancer drug pazopanib by food intake

Erp, van P.H.

MOSAR09 ABILITY

Influence of an acidic beverage (Coca-Cola) on the exposure to Imatinib (Glivec) after major gastrectomy in patients with gastrointestinal stroma tumors

Graaf, van der W.T.A.

Gastro-enterologische tumoren Externe code

Titel

Onderzoeker

MOGE01 ORCHESTRA

A randomized multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and maximal tumor debulking versus chemotherapy alone

Radema, S.A.

MOGE06 IMPACT CRC Colon

Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer

Desar, I.M.E.

MOGE09 CAIRO4

The role of surgery of the primary tumour with few or absent symtoms in patients with synchronous unresectable metastases of colon cancer

Radema, S.A.

MOGE18 CAIRO5

Treatment strategies in colorectal cancer patients with initially unresectable liveronly metastases; CAIRO5 - a randomised phase 3 study of the Dutch Colorectal Cancer Group (DCCG)

Radema, S.A.

MOGE19 PELICAN

Pancreatic locally advanced irresectable cancer ablation in the Netherlands

Stommel, M.

MOGE23 HALO

A phase 3, randomized, double-blind, placebo-controlled, multicenter study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in subjects with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma

Radema, S.A.

MOGE26CAIRO6

Perioperative systemic therapy and surgery versus surgery alone for resectable colorectal peritoneal metastases: the multicentre, phase II-III, randomised CAIRO6 study

Radema, S.A.

Studies open voor inclusie – Afdeling Medische Oncologie – Radboudumc Juni 2018

1


Gynaecologische tumoren Externe code

Titel

Onderzoeker

MOGYN16 i.p. chemo

Predictive factors and pharmacokinetics of intraperitonal chemotherapy

Ottevanger, P.B.

MOGYN18 EORTC 55092

Phase Ib-II, open label, multicenter feasibility study of pazopanib in combination with paclitaxel and carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma

Ottevanger, P.B.

MOGYN20 - CiP

Cancer in Pregnancy (CIP-study) - An international observational study

Ottevanger, P.B.

MOGYN21 QuOTE

Quality of care regarding ovarian cancer therapy Effects

Ottevanger, P.B.

MOGYN23 EORTC55102

A phase III Trial of postoperative chemotherapy or no further treatment for patients withnode-negative stage I-II intermediate or high risk endometrial cancer

Ottevanger, P.B.

MOGYN24 – EORTC1508

A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

Ottevanger, P.B.

MOGYN26 – Ascites OC

Epithelial ovarian cancer 3D tumor cultures for testing drug sensitivity

Ottevanger, P.B.

Hoofd-hals tumoren Externe code

Titel

Onderzoeker

MOHN02 EORTC 1206

A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)

Herpen, van C.M.L.

MOHN06 EORTC 1209EnTF

A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as secondline therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.

Netea-Maier, R.T.

Mamma tumoren Externe code

Titel

Onderzoeker

MOMAM19 FORESIGHT

Foreseeing the moments of occurrence of everolimus long-term side effects by follow up of trough whole blood concentrations

Herpen, van C.M.L.

Studies open voor inclusie – Afdeling Medische Oncologie – Radboudumc Juni 2018

2


Miscellaneous Externe code

Titel

Onderzoeker

MOMIS02 Biopsy protocol

Development of a platform for next-generation DNA sequencing based personalized treatment for cancer patients: Protocol to obtain biopsies from patients with locally advanced (incurable) or metastatic cancer (CPCT - 02 biopsy protocol)

Herpen, van C.M.L.

MOMIS04 DRUP studie

A national study to facilitate patient access to commercially available, targeted anti-cancer drugs to determine the potentialefficacy in treatment of advanced cancers with a known molecular profile - the Drug Rediscovery Protocol (DRUP) trial

Herpen, van C.M.L.

MOMIS06 CHOICE

CHOICE: CHOosing treatment together In Cancer at the End of life

Ottevanger, P.B.

Dermatologische tumoren (melanoom) Externe code

Titel

Onderzoeker

MOMEL16 REPOSIT

A phase II, open-label multicenter study of vemurafenib plus cobimetinib (GDC0973) in unresectable stage IIIc or metastatic melanoma

Koornstra, R.H.T.

MOMEL24 MIND-DC studie

A randomized, double-blind, placebo-controlled phase III study to evaluate active immunization in adjuvant therapy of patients with stage IIIB and IIIC melanoma with natural dendritic cells pulsed with synthetic peptides

Gerritsen, W.R.

MOMEL27 COWBOY

Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600E/K mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY)

Koornstra, R.H.T.

MOMEL29Regeneron R2810-1606

An exploratory tumor biopsy-driven study to understand the relationship between biomarkers and indicators of clinical response in immunomodulatory treatmentnaïve unresectable stage III/IV melanoma patients receiving REGN2810 (antiPD-1)

Gerristen, W.R.

Bot en weke delen tumoren Externe code

Titel

Onderzoeker

MOSAR11 GIST Biodatabank (GALOPPE)

Gastrointestinal stromal tumors bio-databank: assessment of mutations in tumors and in circulating tumor DNA and measurement of TKI plasma exposure to optimize treatment

Desar, I.M.E.

MOSAR19 SSG-XXI GIST

Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study

Desar, I.M.E.

Studies open voor inclusie – Afdeling Medische Oncologie – Radboudumc Juni 2018

3


MOSAR21 – QUEST

Impact of the diagnostic trajectory in sarcoma patients on stage at diagnosis, primary treatment, clinical outcome and quality of life

Desar, I.M.E.

Urologische tumoren Externe code

Titel

Onderzoeker

MOURO02 SURE

Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma

Mulder, S.F.

MOURO15vaccinatie mCRPC

A randomized phase lla study: natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients

Gerritsen, W.R.

MOURO20 – MK3475-199

Phase II trial of pembrolizumab (MK-3475) in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC) previously treated with chemotherapy

Gerritsen, W.R.

MOURO22 – Javelin Blaas B9991001

A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab* (msb0010718c) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy

Gerritsen, W.R.

MOURO24PROFOUND

A phase 3, open label, randomized study to assess the efficacy and safety of olaparib (lynparza) versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations

Mehra, N.

MOURO27AURIMPCA-2

Algorithm for the use of Radium-223 in metastatic prostate cancer. A multicenter, prospective cohort study

Doelen, van der M.

MOURO28Immotion

A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy

Herpen, van C.M.L.

MOURO30 – MODRA M17DOC

Multicenter safety, feasibility and pharmacokinetic phase II trial of ModraDoc006/r in patients with metastatic castration-resistant prostate cancer (M17DOC)

Mehra, N.

Recent gestarte studies Indien u nadere informatie wenst over een studie van afdeling Medische Oncologie, dan kunt u via email contact opnemen met de hoofdonderzoeker. M. Boers-Sonderen

-

Marye.Boers-Sonderen@radboudumc.nl

I. Desar

-

Ingrid.Desar@radboudumc.nl

Studies open voor inclusie – Afdeling Medische Oncologie – Radboudumc Juni 2018

4


W. Gerritsen

-

Winald.Gerritsen@radboudumc.nl

W.T.A. van der Graaf

-

Winette.vanderGraaf@radboudumc.nl

K. Herbschleb

-

Karin.Herbschleb@radboudumc.nl

C. van Herpen

-

Carla.vanHerpen@radboudumc.nl

S.E.J. Kaal

-

Suzanne.Kaal@radboudumc.nl

J.J.M. van der Hoeven

-

Koos.vanderHoeven@radboudumc.nl

R. Koornstra

-

Rutger.Koornstra@radboudumc.nl

N. Mehra

-

Niven.Mehra@radboudumc.nl

S. Mulder

-

Sasja.Mulder@radboudumc.nl

P. Ottevanger

-

Nelleke.Ottevanger@radboudumc.nl

S. Radema

-

Sandra.Radema@radboudumc.nl

Studies open voor inclusie – Afdeling Medische Oncologie – Radboudumc Juni 2018

5

Medonco studies open voor inclusie 03 2017  
Medonco studies open voor inclusie 03 2017